NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31

NRX Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$2.63+0.03 (+1.15%)

Close on Oct 19, 2026

Market cap: $99.02M
P/E (TTM): –
Dividend yield: –

NRX Pharmaceuticals, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Revenue	1.23	0	0	–	–	–	–	–
Cost of Revenue	0.51	0	–	–	–	–	–	–
Gross Profit	0.72	0	–	–	–	–	–	–
Research & Development	3.78	6.20	13	17	20	11	–	–
Selling, General & Admin	13	14	–	–	–	–	–	–
General & Administrative	–	14	14	27	75	11	–	–
Operating Expenses	–	19	28	44	116	51	0.71	1.01
Total Costs & Expenses	17	19	–	–	–	–	–	–
Operating Income	-16	-19	-28	-44	-116	-51	-0.71	-1.01
Interest Expense	0.67	0.23	0.12	–	0.02	0.06	–	–
Interest & Investment Income	0.01	0.04	0.49	0.25	–	–	–	–
Income from Equity Investments	0.04	0	–	–	–	–	–	–
Other Non-Operating Income	-12	-6.62	-2.31	4.58	23	-0.39	1.21	1.09
Asset Impairment Charges	0	0	–	–	–	–	–	–
Legal Settlements	-0.04	1.20	-0.25	–	–	–	–	–
Pretax Income	–	–	–	-40	-93	-52	0.49	0.08
Income Tax Expense	0	0	0	–	–	0.02	0.08	0.02
Net Income incl. Noncontrolling Interests	–	–	-30	-40	-93	–	–	–
Net Income	-29	-25	-30	-40	-93	-52	0.41	0.07
Net Income to Common	–	-25	-30	-40	-349	-52	-0.30	-0.75
EPS (Basic)(per share)	-1.34	-2.36	-3.98	-6.00	-19.80	-15.10	-0.09	-0.24
EPS (Diluted)(per share)	–	–	–	-6.00	-19.80	-15.10	-0.09	-0.24
Shares Outstanding (Basic, Weighted)(shares)	21	11	7.58	6.58	4.69	3.43	3.41	3.20
Shares Outstanding (Diluted, Weighted)(shares)	21	11	7.58	6.58	4.69	3.43	3.41	3.20
EBITDA	-16	-18	–	–	–	–	–	–
Net Interest Income	–	–	–	–	–	0.14	1.21	1.09

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 46.6%
Operating margin: -586.2%
Net margin: -691.8%
Return on equity, FY2025: 146.2%

Financial strength

Current ratio: 0.86
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 78.8%

Valuation

P/E ratio: –
Price to sales: 29.17
Price to book: –
Dividend yield: –